Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

Thomas P. Miller; Stephen E. Jones; David S. Alberts; Cindy Mackel

doi:10.1007/BF00173790

Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

Thomas P. Miller, Stephen E. Jones, David S. Alberts, Cindy Mackel

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M² of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40% of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.

Original language	English (US)
Pages (from-to)	75-77
Number of pages	3
Journal	Investigational New Drugs
Volume	2
Issue number	1
DOIs	https://doi.org/10.1007/BF00173790
State	Published - Mar 1984

Keywords

bisantrene
non-Hodgkin's lymphomas

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00173790

Cite this

@article{670c0a04edc8411b9d7f124fca0992fe,

title = "Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas",

abstract = "Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40% of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.",

keywords = "bisantrene, non-Hodgkin's lymphomas",

author = "Miller, {Thomas P.} and Jones, {Stephen E.} and Alberts, {David S.} and Cindy Mackel",

year = "1984",

month = mar,

doi = "10.1007/BF00173790",

language = "English (US)",

volume = "2",

pages = "75--77",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

AU - Miller, Thomas P.

AU - Jones, Stephen E.

AU - Alberts, David S.

AU - Mackel, Cindy

PY - 1984/3

Y1 - 1984/3

N2 - Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40% of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.

AB - Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40% of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.

KW - bisantrene

KW - non-Hodgkin's lymphomas

UR - http://www.scopus.com/inward/record.url?scp=0021280938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021280938&partnerID=8YFLogxK

U2 - 10.1007/BF00173790

DO - 10.1007/BF00173790

M3 - Article

C2 - 6469502

AN - SCOPUS:0021280938

SN - 0167-6997

VL - 2

SP - 75

EP - 77

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this